Meeting
2020 ASCO Virtual Scientific Program
Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients with diverse malignancies.
Authors
Akram Mesleh Shayeb
University of California San Diego, Moores Cancer Center, La Jolla, CA
Akram Mesleh Shayeb , Razelle Kurzrock , Shumei Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3632)
DOI
10.1200/JCO.2020.38.15_suppl.3632
Abstract #
3632
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.
First Author: Satoshi Fujii
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.
First Author: Joshua Z. Drago
Poster
2023 ASCO Annual Meeting
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.
First Author: Jin Juan